Immunoreactivity and avidity of IgG anti-beta 2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of beta 2-glycoprotein

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10288878" target="_blank" >RIV/00216208:11140/15:10288878 - isvavai.cz</a>

Výsledek na webu

<a href="http://download.springer.com/static/pdf/37/art%253A10.1007%252Fs12026-014-8578-0.pdf?auth66=1423738772_fc2ffef9af6cf6fbbdd25ea557b1c06b&ext=.pdf" target="_blank" >http://download.springer.com/static/pdf/37/art%253A10.1007%252Fs12026-014-8578-0.pdf?auth66=1423738772_fc2ffef9af6cf6fbbdd25ea557b1c06b&ext=.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12026-014-8578-0" target="_blank" >10.1007/s12026-014-8578-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunoreactivity and avidity of IgG anti-beta 2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of beta 2-glycoprotein

Popis výsledku v původním jazyce

The pathogenicity of antibodies against b2-glycoprotein I (anti-b2GPI) depends on multiple factors such as subclass type, epitope binding and avidity. Due to their large heterogeneity, their impact on antiphospholipid syndrome (APS) onset is still not fully clarified. We studied the binding characteristics of IgG anti-b2GPI with known avidity from sera of 201 autoimmune patients (87 with APS, 67 with APS associated with systemic lupus erythematosus (SLE), 47 with only SLE) to six b2GPI peptides corresponding to amino acid clusters on domains I-II, II, III and III-IV by indirect ELISA and evaluated their association with clinical features of APS. Peptides A (LKTPRV; domain I-II), B (KDKATF; domain IV) and C (TLRVYK; domain III) were derived from a hexapeptide phage display library previously shown to react with pathogenic monoclonal anti-b2GPI. Peptides D (NGPANSK; domain III), E (YNPLWFV; domain II) and F (KMDGNHP; domain III-IV) represent surface amino acid clusters on b2GPI. The perc

Název v anglickém jazyce

Immunoreactivity and avidity of IgG anti-beta 2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of beta 2-glycoprotein

Popis výsledku anglicky

The pathogenicity of antibodies against b2-glycoprotein I (anti-b2GPI) depends on multiple factors such as subclass type, epitope binding and avidity. Due to their large heterogeneity, their impact on antiphospholipid syndrome (APS) onset is still not fully clarified. We studied the binding characteristics of IgG anti-b2GPI with known avidity from sera of 201 autoimmune patients (87 with APS, 67 with APS associated with systemic lupus erythematosus (SLE), 47 with only SLE) to six b2GPI peptides corresponding to amino acid clusters on domains I-II, II, III and III-IV by indirect ELISA and evaluated their association with clinical features of APS. Peptides A (LKTPRV; domain I-II), B (KDKATF; domain IV) and C (TLRVYK; domain III) were derived from a hexapeptide phage display library previously shown to react with pathogenic monoclonal anti-b2GPI. Peptides D (NGPANSK; domain III), E (YNPLWFV; domain II) and F (KMDGNHP; domain III-IV) represent surface amino acid clusters on b2GPI. The perc

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Immunologic Research

ISSN

0257-277X

e-ISSN

—

Svazek periodika

61

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

35-44

Kód UT WoS článku

000349004900006

EID výsledku v databázi Scopus

2-s2.0-84925490713